10 Added | 1 Magazine | @JKConsulting | Let's accept the hard fact "The goal of all investors and organizations is to achieve monetizing event, such as the ability to raise capital, perform meaningful r&d, license prototypes, poc or simply patents or commercialize products, reach profitability or execute a strategic transaction.JKConsulting comprises of network of experts and service provider having deep knowledge in drug discovery, product development patent, corporate law, finance and commercialization enabling our clients achieve a faster path to their R&D monetizing events.

A Bearish Assessment on Biotech ETFs

RELATED ARTICLES<p>The <b>iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB)</b>, the largest biotech exchange traded fund by assets, is off more than 5% over the …

TILT Biotherapeutics Secures 10 M€ ($10.6M) for Viral Cancer T-Cell Immunotherapy

HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics Ltd, the oncolytic immunotherapy startup founded in<br>2013, has closed a financing round of 4.0M€ (~$4.3M) …

BioCardia Receives US Patent Covering a Method of Treating Heart Attack Tissue Damage with a Patient’s Own Progenitor Cells, Providing Further Protection to Phase III CardiAMP Program

SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc., (OTC:BCDA), a leader in the development of<br>comprehensive solutions for cardiovascular …

Small Companies Thinking Big: China Tactical Strategies

Sub-Saharan Africa

This genius chemist spent 50 years creating psychedelic drugs in his home lab…for a good cause

For Alexander Shulgin, MDMA had huge therapeutic potential<p>I am sitting in the garden of the late godfather of psychedelics, Dr. Alexander “Sasha” …

New York Times